NexImmune, Inc.: Nasdaq/NYSE listing notice — NexImmune receives Nasdaq deficiency notice for bid price below $1.00

NexImmune, Inc.

Deficiency letter received Oct 25, 2022; stock closed below $1.00 for 30 consecutive business days.
Company has 180 days, until April 24, 2023, to regain compliance with Minimum Bid Price Requirement.
If non-compliant, may transfer listing to Nasdaq Capital Market or face delisting.
Company may consider options including reverse stock split to cure deficiency.
No immediate effect on listing; stock continues trading on Nasdaq under symbol NEXI.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NexImmune, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

October 25, 2022, NexImmune, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and it

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-22-272490

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.